CTIM-76 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer
CNTX has more than doubled off its 52-week low of $0.49 on light trading volume (0.2× avg).
Summary
Context Therapeutics announced that its drug candidate, CTIM-76, has received FDA Fast Track Designation for the treatment of platinum-resistant ovarian cancer. This designation is a significant positive regulatory milestone, as it is designed to expedite the development and review of drugs addressing serious conditions with unmet medical needs, potentially accelerating CTIM-76's path to market. This news builds on the positive momentum from March 23, 2026, when the company reported a confirmed partial response in its Phase 1a trial for CTIM-76. Investors will now be watching for the interim data from the CTIM-76 program, which is expected in June 2026.
At the time of this announcement, CNTX was trading at $2.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.5M. The 52-week trading range was $0.49 to $3.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.